首页> 外文期刊>Nanotechnology >Sucrose ester stabilized solid lipid nanoparticles and nanostructured lipid carriers: I. Effect of formulation variables on the physicochemical properties, drug release and stability of clotrimazole-loaded nanoparticles
【24h】

Sucrose ester stabilized solid lipid nanoparticles and nanostructured lipid carriers: I. Effect of formulation variables on the physicochemical properties, drug release and stability of clotrimazole-loaded nanoparticles

机译:蔗糖酯稳定的固体脂质纳米颗粒和纳米结构脂质载体:I.配方变量对载有克霉唑的纳米颗粒的理化性质,药物释放和稳定性的影响

获取原文
获取原文并翻译 | 示例
           

摘要

The objective of this study was to develop and evaluate solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) utilizing sucrose ester as a stabilizer/emulsifier for the controlled release of drug/active. Both SLNs and NLCs were prepared using different sugar esters to screen out the most suitable stabilizer. Clotrimazole was used as a model active/drug. The effect of different formulation variables on the particle size, polydispersity index and drug encapsulation efficiency of SLNs and NLCs was evaluated and compared. SLNs and NLCs were physicochemically characterized and compared using Cryo-SEM, DSC and XRD. Furthermore, a drug release study of SLNs and NLCs was conducted. Finally, physicochemical stability (size, PI, ZP, EE) of the SLNs and NLCs was checked at 25±2 ℃ and at 2–8 ℃. Among the sucrose esters, D-1216 was found to be most suitable for both SLNs and NLCs. Formulation variables exhibited a significant impact on size, PI and EE of the nanoparticles. SLNs with ~120 nm size, ~0.23 PI, ~I26I mV ZP, ~87% EE and NLCs with ~160 nm size, 0.15 PI, ~I26I mV ZP, ~88% EE were produced. Cryo-SEM revealed spherical particles with a smooth surface but did not exhibit any difference in surface morphology between SLNs and NLCs. DSC and XRD results demonstrated the disappearance of clotrimazole peak(s) in drug-loaded SLNs and NLCs. Faster drug release was observed from SLNs than NLCs. NLCs were found to be more stable than SLNs in terms of size, PI, EE and drug release. The results indicated that both SLNs and NLCs stabilized with sucrose ester D-1216 can be used as controlled release carriers although NLCs have an edge over SLNs.
机译:这项研究的目的是开发和评估利用蔗糖酯作为稳定剂/乳化剂以控制药物/活性成分释放的固体脂质纳米颗粒(SLN)和纳米结构脂质载体(NLC)。 SLN和NLC均使用不同的糖酯制备,以筛选出最合适的稳定剂。克霉唑用作模型活性剂/药物。评估并比较了不同配方变量对SLNs和NLCs的粒径,多分散指数和药物包封效率的影响。对SLN和NLC进行理化鉴定,并使用Cryo-SEM,DSC和XRD进行比较。此外,进行了SLN和NLC的药物释放研究。最后,在25±2℃和2–8℃下检查了SLN和NLC的理化稳定性(大小,PI,ZP,EE)。在蔗糖酯中,发现D-1216最适合SLN和NLC。配方变量对纳米颗粒的尺寸,PI和EE表现出显着影响。产生了〜120 nm尺寸,〜0.23 PI,〜I26I mV ZP,〜87%EE的SLN和〜160 nm尺寸,0.15 PI,〜I26I mV ZP,〜88%EE的NLC。 Cryo-SEM显示球形颗粒具有光滑的表面,但SLN和NLC之间的表面形态没有任何差异。 DSC和XRD结果表明,载药的SLN和NLC中克霉唑峰的消失。观察到SLN比NLC释放的药物更快。发现NLC在大小,PI,EE和药物释放方面比SLN更稳定。结果表明尽管蔗糖酯D-1216稳定的SLN和NLC都比SLN有优势,但它们都可用作控释载体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号